TipRanks
Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ:COAG
US Market
COAG
Hemab Therapeutics Holdings, Inc.
RESEARCH TOOLSreports

Hemab Therapeutics Holdings, Inc. (COAG) Income Statement

15 Followers

Hemab Therapeutics Holdings, Inc. Income Statement

Last quarter (Q2 2026), Hemab Therapeutics Holdings, Inc.'s total revenue was $0.00, a decrease of ― from previous quarter. In Q2, Hemab Therapeutics Holdings, Inc.'s net income was $-24.15M. See Hemab Therapeutics Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25
Total Revenue
$ 0.00
Gross Profit
$ 0.00
Operating Expenses
$ 70.12M
Depreciation and Amortization
$ 304.00K
EBITDA
$ -69.81M
Operating Income
$ -70.12M
Other Income/Expenses
$ 5.98M
Pretax Income
$ -64.14M
Net Income
$ -63.91M
Per Share Metrics
Basic EPS
$ -2.33
Diluted EPS
$ -2.33
Weighted Average Shares Outstanding
 27.44M
Weighted Average Shares Outstanding (Diluted)
 27.44M
Currency in USD

Hemab Therapeutics Holdings, Inc. Earnings and Revenue History